Data gathered: November 27
Alternative Data for Tenaya Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 9,000 | Sign up | Sign up | Sign up |
| Employee Rating | 70 | Sign up | Sign up | Sign up |
| Google Trends | 58 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 200 | Sign up | Sign up | Sign up |
| Facebook Followers | 3,675 | Sign up | Sign up | Sign up |
| Instagram Followers | 63 | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 42 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,020 | Sign up | Sign up | Sign up |
| Twitter Followers | 360 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 88 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 76 | Sign up | Sign up | Sign up |
| Linkedin Employees | 131 | Sign up | Sign up | Sign up |
About Tenaya Therapeutics
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.
| Price | $3.29 |
| Target Price | Sign up |
| Volume | 8,290,000 |
| Market Cap | $234M |
| Year Range | $1.64 - $5.23 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Tenaya Therapeutics Doses First Patient in RIDGE-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular CardiomyopathyNovember 25 - Finnhub |
|
Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular CardiomyopathyNovember 24 - Finnhub |
|
 |
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Shares Sold by GSA Capital Partners LLPNovember 24 - ETF Daily News |
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(4)November 19 - Finnhub |
|
 |
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)November 18 - Yahoo |
 |
Tenaya Therapeutics SVP sells $4,786 in stockNovember 18 - Investing.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 8.5M | -8.5M | -26M | -25M | -0.300 |
| Q2 '24 | 0 | 10M | -10M | -29M | -29M | -0.340 |
| Q1 '24 | 0 | 11M | -11M | -32M | -32M | -0.400 |
| Q4 '23 | 18M | 11M | -11M | -30M | -29M | -0.400 |
| Q3 '23 | 0 | 10M | -10M | -29M | -29M | -0.390 |
Insider Transactions View All
| Saito Chihiro filed to sell 60,983 shares at $2.1. November 18 '24 |
| Saito Chihiro filed to sell 64,048 shares at $2.9. August 19 '24 |
| Saito Chihiro filed to sell 63,241 shares at $2.9. August 19 '24 |
| Saito Chihiro filed to sell 64,702 shares at $2.9. August 19 '24 |
| Ali Faraz filed to sell 188,331 shares at $2.9. August 16 '24 |
Similar companies
Read more about Tenaya Therapeutics (TNYA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Tenaya Therapeutics?
The Market Cap of Tenaya Therapeutics is $234M.
What is the current stock price of Tenaya Therapeutics?
Currently, the price of one share of Tenaya Therapeutics stock is $3.29.
How can I analyze the TNYA stock price chart for investment decisions?
The TNYA stock price chart above provides a comprehensive visual representation of Tenaya Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Tenaya Therapeutics shares. Our platform offers an up-to-date TNYA stock price chart, along with technical data analysis and alternative data insights.
Does TNYA offer dividends to its shareholders?
As of our latest update, Tenaya Therapeutics (TNYA) does not offer dividends to its shareholders. Investors interested in Tenaya Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Tenaya Therapeutics?
Some of the similar stocks of Tenaya Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.